(Q40809519)

23 September 2017

Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units (English)

1 reference

23 September 2017

T Petit

1

1 reference

23 September 2017

E Izbicka

2

1 reference

23 September 2017

R A Lawrence

3

1 reference

23 September 2017

W R Bishop

4

1 reference

23 September 2017

S Weitman

5

1 reference

23 September 2017

D D Von Hoff

6

1 reference

23 September 2017

1 April 1999

1 reference

23 September 2017

1 reference

23 September 2017

10

1 reference

23 September 2017

449-453

1 reference

23 September 2017

4

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

23 September 2017

1 reference

7 January 2021

The ras gene family and human carcinogenesis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

All ras proteins are polyisoprenylated but only some are palmitoylated

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Ras C-terminal processing enzymes--new drug targets?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Farnesyltransferase inhibitors: Ras research yields a potential cancer therapeutic

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumo

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Antitumor 8-chlorobenzocycloheptapyridines: a new class of selective, nonpeptidic, nonsulfhydryl inhibitors of ras farnesylation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Primary Bioassay of Human Tumor Stem Cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Polylysine and CVIM sequences of K-RasB dictate specificity of prenylation and confer resistance to benzodiazepine peptidomimetic in vitro.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Proteins regulating Ras and its relatives

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008313232381

7 January 2021

Identifiers

DOI

10.1023/A:1008313232381

1 reference

23 September 2017

1 reference